Edward Tuddenham is emeritus Professor of Haemophilia at University College London.
Prof. Tuddenham received his medical degree from the University of London in 1968. In his first post as a trainee pathologist at the Royal Victoria Infirmary in Liverpool, he developed a keen interest in haemophilia sparked by observing a patient with inhibitory antibody to factor VIII. For further training in haematology, he moved to Cardiff and started working on factor VIII under the guidance of Arthur Bloom, which he continued at the University of Connecticut, USA in the laboratory of Leon Hoyer. He was appointed as first director of the new Haemophilia Centre at Royal Free Hospital in London, where he was the immediate successor of Katharine Dormandy in 1978. From 1978 to 1982 his group completed the first large scale purification to homogeneity of human factor VIII. This enabled the sequencing of the protein, cloning of its gene and production of recombinant factor VIII in cultured cells, achieved in 1984 in collaboration with teams at Genentech Inc. In 1987 he left the Haemophilia Centre to set up the Haemostasis Research Group for the Medical Research Council, which he led for 20 years. During this time, his group made many advances in rare bleeding disorders such as deficiency of factor VII, factor XI, combined factor V and VIII and platelet function disorders. He returned to the Royal Free Hospital Katharine Dormandy Haemophilia Centre in 2006 and remained Director until his retirement in 2011. During that time his group initiated the first safe effective gene therapy for haemophilia B, work which was carried out in collaboration with Professor Amit Nathwani, (who became Tuddenham’s successor as Director of the Katharine Dormandy Haemophilia Centre) and teams at St Jude Children’s Research Hospital, Memphis, TN.
Prof. Tuddenham has published over 300 original scientific papers, review articles, book chapters and books
His current research interests are the establishment of gene therapies Haemophilia A, Haemophilia B and factor VII deficiency and the structure, function and interaction of factor VIII with other proteins. He is also interested in ways to make affordable therapy available worldwide in resource poor countries.